Background : There were no published data regarding the clinical efficacy and safety of second generation drug-eluting stent (zotarolimus-eluting stent with biolinx polymer, ZES-BP, Endeavor resolute) following primary percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI). We evaluated the one-year outcome of zotarolimus-eluting stent with biolinx polymer versus to 1st generation (sirolimus-eluting stent, SES and paclitaxel-eluting stent, PES) and 2nd generation (zotarolimus-eluting stent, ZES and everolimus-eluting stent, EES) drug-eluting stents(DES) for the treatment of STEMI.
Methods : A prospective, open-labeled, multi-center cohort has been performed at 4 centers in Korea. All patients will be clinically followed-up for two years. The primary endpoint was major adverse cardiac event (MACE): the composite of cardiac death (CD), recurrent MI and ischemia-driven target vessel revascularization (TVR) at 1 year. Stent thromboses (ST) by ARC definition were analyzed.
Results : Total 975 patients (ZES-BP=178, EES=197, ZES=203, SES=203, PES=194) who were completed more than one year were analyzed. One-year MACE were 3.4%, 2.0%, 5.9%, 3.4% and 5.7% in ZES-BP, EES, ZES, SES and PES group, respectively (p=ns). Cardiac death were 2.3%, 1.0%, 2.5%, 1.5% and 1.0% in ZES-BP, EES, ZES, SES and PES group, respectively (p=ns). ST were 0%, 0%, 2.0%, 2.0% and 2.0% in ZES-BP, EES, ZES, SES and PES group, respectively (p=ns).
Conclusions: Campared to 1st and 2nd generation DES (SES and PES, ZES), EES and ZES-BP showed similar one-year clinical outcomes in terms of MACE in patients with STEMI following primary PCI and no stent thrombosis.
|
